Sign in

    Matthew Guggenbiller • Bank of America

    Matthew Guggenbiller's questions to Intellia Therapeutics Inc (NTLA) leadership

    Matthew Guggenbiller's questions to Intellia Therapeutics Inc (NTLA) leadership • Q2 2025

    Question

    Representing Alex Stranahan of Bank of America, Matthew Guggenbiller asked if the changes to enrollment targets and stabilizer percentage in the MAGNITUDE study have altered the company's thinking on the likelihood or timing of a potential interim readout.

    Answer

    President and CEO John Leonard confirmed that the adjustments increase the overall statistical power of the study for both the primary outcome and the stabilizer subgroup. He stated an expectation that these changes would "favorably affect the ability to find an effect" at the point of a future interim analysis.

    Ask Fintool Equity Research AI

    Matthew Guggenbiller's questions to Agios Pharmaceuticals Inc (AGIO) leadership

    Matthew Guggenbiller's questions to Agios Pharmaceuticals Inc (AGIO) leadership • Q2 2025

    Question

    Matthew Guggenbiller of Bank of America inquired about the educational strategy to drive Pyrokine uptake beyond the initial target patients in thalassemia and asked if development plans for the PKU asset, AG-181, have changed following a competitor's recent approval.

    Answer

    CCO Tsveta Milanova detailed plans to expand to less acute non-transfusion-dependent patients by educating on long-term complications. CMO Dr. Sarah Gheuens stated there are no changes to the PKU program, emphasizing AG-181's novel mechanism and the remaining unmet need in the patient population.

    Ask Fintool Equity Research AI